A&G Pharmaceutical Receives 2009 Maryland Business Incubator Award
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
A&G Pharmaceutical received the “Best Graduate Company” Award at the 2009 Maryland Incubator of the Year Awards on June 16, 2009.
The award was presented in recognition of the company’s diagnostic products in development based on a biological target, or biomarker, discovered by A&G researchers known as GP88/PGRN, which plays a critical role in helping the cancer to grow and proliferate.
A&G initiated operations in 2000 in the Emerging Technology Center incubator in Baltimore to develop and commercialize linked therapeutic-diagnostic products for personalized medicine based on its biomarker discoveries, with a focus on cancer.
The company, which now has 22 employees, has two diagnostic tests for breast cancer in clinical trials, a linked breast cancer therapeutic in development, and additional longer-term diagnostic products in development for lung cancer and prostate cancer.
“We are very pleased that the Maryland business community has bestowed the honor of Best Graduate Company on A&G,” said Ginette Serrero, PhD, Chief Executive Officer of A&G. “We could not accept this award without acknowledging Ann Lansinger, President of the Emerging Technology Centers, who provided the critical assistance at A&G’s inception that enabled us to incubate.
The award was presented in recognition of the company’s diagnostic products in development based on a biological target, or biomarker, discovered by A&G researchers known as GP88/PGRN, which plays a critical role in helping the cancer to grow and proliferate.
A&G initiated operations in 2000 in the Emerging Technology Center incubator in Baltimore to develop and commercialize linked therapeutic-diagnostic products for personalized medicine based on its biomarker discoveries, with a focus on cancer.
The company, which now has 22 employees, has two diagnostic tests for breast cancer in clinical trials, a linked breast cancer therapeutic in development, and additional longer-term diagnostic products in development for lung cancer and prostate cancer.
“We are very pleased that the Maryland business community has bestowed the honor of Best Graduate Company on A&G,” said Ginette Serrero, PhD, Chief Executive Officer of A&G. “We could not accept this award without acknowledging Ann Lansinger, President of the Emerging Technology Centers, who provided the critical assistance at A&G’s inception that enabled us to incubate.
